Innovation and the Pharmaceutical Industry
 | Critical Reflections on the Virtues of Profit Edited by H. Tristram Engelhardt, Jr. and Jeremy R. Garrett Series: Conflicts and Trends: Studies in Values and Policies Copyright: 2008 | Status: Published ISBN: 9780980209440 | Hardcover | 1.25 lbs 252 pages Price: $69 USD  |
Short Description
The book examines the central role of profit in the development of pharmaceuticals, medical devices, and health care generally. Balancing a concern for theory and practice, the analyses and evaluations provided in these essays touch directly on many of the most heated and important debates in pharmaceutical ethics, such as profit margins, corporate social responsibility, drug advertising, litigation, patents, and parallel trade.
Audience
· Professionals (managers, scientists, lawyers) working in drug development in the pharmaceutical industry.
· Business ethicists and bioethicists in business, academic, and industry settings.
· Health policy experts
· Health lawyers
· Professionals (managers, scientists, lawyers) working in drug development in the pharmaceutical industry.
· Business ethicists and bioethicists in business, academic, and industry settings.
· Health policy experts
· Health lawyers
Description
Innovation and the Pharmaceutical Industry: Critical Reflections on the Virtues of Profit examines the central role of profit in the development of pharmaceuticals, medical devices, and health care generally. Recent efforts to understand this role have often underestimated and even dismissed its importance, arguing for its replacement by other means and mechanisms. However, as the essays in this volume attest, it would be impossible to account adequately for the range of pharmaceuticals and medical devices that have become part of everyday medicine without recognizing that the depth and scope of innovations are tied not simply to altruism, a concern for the common good, or the pursuit of knowledge for its own sake, but crucially to the pursuit of private good and of individual profit.
Balancing a concern for theory and practice, the analyses and evaluations provided in these essays touch directly on many of the most heated and important debates in pharmaceutical ethics, such as profit margins, corporate social responsibility, drug advertising, litigation, patents, and parallel trade. Reflecting critically on the problems and prospects of medical innovation, they invite a rethinking of the foundations of the bioethics and business ethics of the pharmaceutical and medical device industries by focusing on the long-term impact of policy decisions for human health and well-being.
Back to Top
Innovation and the Pharmaceutical Industry: Critical Reflections on the Virtues of Profit examines the central role of profit in the development of pharmaceuticals, medical devices, and health care generally. Recent efforts to understand this role have often underestimated and even dismissed its importance, arguing for its replacement by other means and mechanisms. However, as the essays in this volume attest, it would be impossible to account adequately for the range of pharmaceuticals and medical devices that have become part of everyday medicine without recognizing that the depth and scope of innovations are tied not simply to altruism, a concern for the common good, or the pursuit of knowledge for its own sake, but crucially to the pursuit of private good and of individual profit.
Balancing a concern for theory and practice, the analyses and evaluations provided in these essays touch directly on many of the most heated and important debates in pharmaceutical ethics, such as profit margins, corporate social responsibility, drug advertising, litigation, patents, and parallel trade. Reflecting critically on the problems and prospects of medical innovation, they invite a rethinking of the foundations of the bioethics and business ethics of the pharmaceutical and medical device industries by focusing on the long-term impact of policy decisions for human health and well-being.
Back to Top
Reviews
"Engelhardt and Garrett have assembled a sorely needed text bringing clarity to the brassy, yet one-dimensional, criticisms of profit in the pharmaceutical industry. It would certainly serve as a foundational reference for those in the pharmaceutical and medical device industry, those interested in bioethics or medical business ethics, or anyone looking for a more balanced account of this debate. Innovation and the Pharmaceutical Industry is the reigning exposition on why the market and the pursuit of profit are the superior mechanism."
Erica K. Rangel, HEC Forum
"Engelhardt and Garrett have assembled a sorely needed text bringing clarity to the brassy, yet one-dimensional, criticisms of profit in the pharmaceutical industry. It would certainly serve as a foundational reference for those in the pharmaceutical and medical device industry, those interested in bioethics or medical business ethics, or anyone looking for a more balanced account of this debate. Innovation and the Pharmaceutical Industry is the reigning exposition on why the market and the pursuit of profit are the superior mechanism."
Erica K. Rangel, HEC Forum
"This book will prove indispensable in future debate on the appropriate place of profit in the pharmaceutical industry."
Cambridge Quarterly of Healthcare Ethics
Cambridge Quarterly of Healthcare Ethics
Back to Top
Author / Editor Details
H. Tristram Engelhardt, Jr., holds degrees in both medicine and philosophy. He is Professor in the Department of Philosophy at Rice University, Professor Emeritus in the Department of Medicine, Baylor College of
H. Tristram Engelhardt, Jr., holds degrees in both medicine and philosophy. He is Professor in the Department of Philosophy at Rice University, Professor Emeritus in the Department of Medicine, Baylor College of
Jeremy R. Garrett Ph.D., Department of Philosophy, California State University, Sacramento
Back to Top
Table of Contents
Martin D. Beirne: Preface.
I. INTRODUCTION
H. Tristram Engelhardt, Jr. & Jeremy R. Garrett: Pharmaceutical Innovation and the Market: The Pursuit of Profit and the Amelioration of the Human Condition.
II. THE SOCIAL RESPONSIBILITY OF PURSUING PROFIT
H. Tristram Engelhardt, Jr.: The Unavoidable Goodness of Profit: The Cunning of Reason and the Realization of Human Well-Being.
Nicholas Capaldi: Corporate Social Responsibility and Business Ethics in the Pharmaceutical Industry.
Pepe Lee Chang: Pharmaceutical Companies and Their Obligations to Developing Countries: Psychopaths or Scapegoats?
III. AUTONOMY, ADVERTISING, AND PHARMACEUTICAL COSTS
James Stacy Taylor: Autonomy, Constraining Options, and Pharmaceutical Costs.
Andrew I. Cohen: Pharmaceutical Advertising and Patient Autonomy.
IV. SOME CRITICISMS OF THE PHARMACEUTICAL INDUSTRY CRITICALLY RE-EXAMINED
Richard A. Epstein: Why America does not have a Second Drug Problem?
Michael A. Rie: Global Drug Innovation in a World of Financial Finitude: Retailing Virtue to Promote Capital Formation and Profit.
V. MARKETS, PHARMACEUTICALS, AND HEALTH SAVINGS ACCOUNTS
John C. Goodman: Time, Money, and the Market for Drugs.
John R. Graham: Perils of Parallel Trade: Reimporting Prescription Drugs from Canada to the U.S.
VI. PHARMACEUTICAL LIABILITY: ANOTHER SOURCE OF HEALTH CARE COSTS
Sandra H. Johnson & Ana Smith Iltis: Risk, Responsibility, and Litigation.
Back to Top
Martin D. Beirne: Preface.
I. INTRODUCTION
H. Tristram Engelhardt, Jr. & Jeremy R. Garrett: Pharmaceutical Innovation and the Market: The Pursuit of Profit and the Amelioration of the Human Condition.
II. THE SOCIAL RESPONSIBILITY OF PURSUING PROFIT
H. Tristram Engelhardt, Jr.: The Unavoidable Goodness of Profit: The Cunning of Reason and the Realization of Human Well-Being.
Nicholas Capaldi: Corporate Social Responsibility and Business Ethics in the Pharmaceutical Industry.
Pepe Lee Chang: Pharmaceutical Companies and Their Obligations to Developing Countries: Psychopaths or Scapegoats?
III. AUTONOMY, ADVERTISING, AND PHARMACEUTICAL COSTS
James Stacy Taylor: Autonomy, Constraining Options, and Pharmaceutical Costs.
Andrew I. Cohen: Pharmaceutical Advertising and Patient Autonomy.
IV. SOME CRITICISMS OF THE PHARMACEUTICAL INDUSTRY CRITICALLY RE-EXAMINED
Richard A. Epstein: Why America does not have a Second Drug Problem?
Michael A. Rie: Global Drug Innovation in a World of Financial Finitude: Retailing Virtue to Promote Capital Formation and Profit.
V. MARKETS, PHARMACEUTICALS, AND HEALTH SAVINGS ACCOUNTS
John C. Goodman: Time, Money, and the Market for Drugs.
John R. Graham: Perils of Parallel Trade: Reimporting Prescription Drugs from Canada to the U.S.
VI. PHARMACEUTICAL LIABILITY: ANOTHER SOURCE OF HEALTH CARE COSTS
Sandra H. Johnson & Ana Smith Iltis: Risk, Responsibility, and Litigation.
Back to Top
BISAC SUBJECT HEADINGS
PHI015000: Philosophy/Ethics & Moral Philosphy
MED050000: Medical Ethics
BUS02000: Business & Economics/Development/Business Development
BIC CODES
PSAD: Bioethics
KNDP: Pharmaceutical Industries
Back to Top